Physician profile
Philip Yam
NPI 1851686554
$3,180.42
in general payments reported to CMS, 2019-2025
12 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $308 · 2024: $1,329 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.15 | 2023-2025 | Vraylar |
| Axsome Therapeutics, INC. | $719.27 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $594.86 | 2023-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Vanda Pharmaceuticals INC. | $589.61 | 2023-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $148.68 | 2023-2024 | Dyanavel Xr |
| Corium, LLC | $95.87 | 2023-2024 | Azstarys |
| Lundbeck LLC | $85.63 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $82.65 | 2025 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $51.08 | 2025 | Rejoyn, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.22 | 2025 | Caplyta |
| Bausch Health US, LLC | $32.18 | 2025 | Wellbutrin, Aplenzin |
| Noven Therapeutics, LLC | $14.22 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Yam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.